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Low oxygen tension is a critical aspect of the stem cell niche where stem cells are 
long-term maintained. In “physiologically hypoxic” stem cell niches, low oxygen tension 
restrains the clonal expansion of stem cells without blocking their cycling, thereby con-
tributing substantially to favor their self-renewal. The capacity of stem cells, hematopoi-
etic stem cells in particular, to reside in low oxygen is likely due to their specific metabolic 
profile. A strong drive to the characterization of this profile emerges from the notion 
that cancer stem cells (CSC), like normal stem cells, most likely rely on metabolic cues 
for the balance between self-renewal/maintenance and clonal expansion/differentiation. 
Accordingly, CSC homing to low oxygen stem cell niches is the best candidate mech-
anism to sustain the so-called minimal residual disease. Thus, the metabolic profile of 
CSC impacts long-term cancer response to therapy. On that basis, strategies to target 
CSC are intensely sought as a means to eradicate neoplastic diseases. Our “metabolic” 
approach to this challenge was based on two different experimental models: (A) the 
Yoshida’s ascites hepatoma AH130 cells, a highly homogeneous cancer cell population 
expressing stem cell features, used to identify, in CSC adapted to oxygen and/or nutrient 
shortage, metabolic features of potential therapeutic interest; (B) chronic myeloid leuke-
mia, used to evaluate the impact of oxygen and/or nutrient shortage on the expression 
of an oncogenetic protein, the loss of which determines the refractoriness of CSC to 
oncogene-targeting therapies.
Keywords: cancer stem cells, microenvironment, metabolism, hypoxia, glucose shortage, chronic myeloid 
leukemia
iNTRODUCTiON
Low oxygen tension is a critical aspect of the environment where stem cells reside. On the basis of 
in vitro data, we were the first to put forward, in 1993, the hypothesis that hematopoietic stem cell 
(HSC) niches, where HSC are physiologically hosted in vivo, are bone marrow areas maintained at 
relatively low oxygen tension (1). Our results, limited to short-term repopulating HSC, were later 
confirmed by others and extended to comprise long-term repopulating HSC (2). The capacity of 
HSC, but not of hematopoietic progenitor cells (HPC), to home in low oxygen tissue areas is crucial 
to ensure HSC self-renewal and long-term maintenance. This capacity is likely due to the specific 
metabolic profile of HSC. We also found that low oxygen does not inhibit HSC cycling but limits 
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cycling to support HSC self-renewal (3). Thus, the environment 
of “physiologically hypoxic” niches (4) contributes substantially 
to maintain stem cell potential. A number of excellent reviews 
addressed the relationship of niche environment to oxygen ten-
sion and blood supply in bone marrow. Moreover, the overall 
architecture of niche, which includes stromal cells, extracellular 
matrix, and soluble or matrix-bound cytokines has also been 
extensively described (5, 6). The physiological role of relatively 
low oxygen tensions in the regulation of stem cell compartments 
was further supported by later studies on pluripotent embryonal 
stem cells. Indeed, in the developing embryo, the inner cell mass 
of blastocyst is a relatively “hypoxic” (pO2 < 2%) structure (7), 
where embryonal stem cells largely rely on glycolytic ATP gen-
eration independently of oxygen shortage (8), i.e., exploiting the 
“aerobic” glycolysis or Warburg effect (9).
Cancer cell populations are usually characterized by a marked 
phenotypical heterogeneity to include differentiating cells as well 
as cancer stem cells (CSC). CSC seem to rely on environmental 
cues similar to those characterizing physiological stem cell niches 
for either their survival or the regulation of balance between 
self-renewal/maintenance and clonal expansion/differentiation. 
CSC continuously interact with non-neoplastic components of 
the niche, which decisively contribute to the maintenance of CSC 
via their protection from insults of different nature coming from 
outside the niche. These insults range from the physiological 
pressure of cytokines boosting clonal expansion at the expense of 
stem cell maintenance to the action of therapeutic agents (10, 11). 
The location itself of the niche may represent a powerful protec-
tion factor. Indeed, being far away from blood vessels implies the 
exposure to significantly lower concentrations of systemically 
administered drugs than in the rest of tissue. Furthermore, 
although CSC are allowed to cycle in the niche, their slow cycling 
or even quiescence provides an obvious protection from the effects 
of chemotherapeutic agents designed to suppress proliferating 
cells (12). On the other hand, CSC hosting in niches at extremely 
low oxygen tension has the straightforward consequence that 
CSC are protected from the effects of reactive oxygen radicals 
(ROS), which are instead typically generated in better oxygenated 
tissue areas. This represents a serious problem in relation to the 
effectiveness of radiotherapy on CSC, which largely relies on ROS 
generation to induce DNA damage in tumor cells (13).
Moreover, it is worth noting here that CSC have intrinsic 
properties that make them resistant to treatments. These proper-
ties, including the expression of aldehyde dehydrogenase and 
of the two ABC transporters MDR1 and ABCG2, which drive 
drug efflux from cells, have been excellently reviewed elsewhere 
(14). The association between multidrug resistance (MDR) and 
stem cell markers in human chronic myeloid leukemia (CML) 
cell lines has been clearly shown (15). The combination of CSC-
intrinsic properties with the CSC-sheltering effects of stem cell 
niche makes it impossible to obtain a homogeneous therapeutic 
efficacy on the whole cancer tissue. In this scenario, CSC homing 
within niches is the best candidate mechanism to sustain minimal 
residual disease (MRD). Such a clinical state may determine late 
relapse of disease even in patients who brilliantly responded to 
therapy undergoing to complete remission. Low oxygen turns 
out to represent “the,” or at least “one of the,” most important 
factors ensuring MRD persistence (16). This implies that CSC, 
like normal stem cells, are capable to metabolically adapt to low 
oxygen. More in general, CSC are capable to adopt a nutrient 
uptake pattern and energy metabolism profile that favors their 
homing into niches (i.e., an adequate interaction between the 
oxygen-sensing and the nutrient-sensing signaling pathways). To 
conclude, one can affirm that the metabolic profile of CSC heavily 
impacts cancer response to therapy.
Modern oncology is testing selective CSC targeting as a 
means to eradicate neoplastic disease (17), aiming at their cure 
rather than care. The latter outcome is, instead, typical of actions 
directed to suppress the proliferating bulk of cancer population. 
Our “metabolic” approach to this challenge was based on two 
different experimental models. We used AH130 ascites hepatoma 
cells (18) to try to identify some step of metabolic pathways, 
which is particularly vulnerable in CSC adapted to low oxygen. 
On the other hand, we choose CML as a model disease to evaluate 
the therapeutic targeting of CSC in cell populations where low 
oxygen determines the suppression of an oncogenetic protein and 
the consequent loss of oncogene addiction.
AH130 CeLLS AS A PROTOTYPe OF 
CANCeR STeM CeLLS
The metabolic studies we summarize here were necessarily pre-
ceded by a reappraisal of the nature of the AH130 cell population. 
This hepatoma can be maintained indefinitely via serial trans-
plantations in the rat peritoneal cavity, where huge amounts of 
immature cells are produced each time. AH130 cells express fun-
damental embryonic transcription factors (ETF), such as Nanog, 
Klf4, and c-Myc. When peritoneal cavity is cell-saturated and 
cell growth is arrested, glucose concentration as well as oxygen 
tension approach 0. In spite of that all hepatoma cells are alive, 
75% of which expressing Nanog and more than 90% the stem cell 
marker CD133 (19). Thus, the AH130 hepatoma is an inexhaust-
ible source of stem cells, which provides a decisive advantage in 
view of the characterization of their metabolic profile.
Well in keeping with the scenario summarized in the 
Introduction, AH130 cells are, like other stem cells, adapted to 
low oxygen (20). The metabolic profile of AH130 cells is indeed 
centered on an extremely high capacity of converting pyruvate 
into lactate, so that cells, when exposed ex vivo to high glucose 
concentrations (upto 15 mM) in air, convert up to 80% of the 
available glucose to lactate, exhibiting an excellent example 
of Warburg metabolism. This enormous energy waste implies 
that the elimination of pyruvate produced by aerobic glycolysis 
is a primary exigency, due to a detrimental effect of pyruvate 
accumulation on G1–S transition. A key finding to understand 
the mechanism of this effect was that the addition of exogenous 
pyruvate to AH130 cells (incubated in air in the presence of 
15-mM glucose) faithfully mimicked that of antimycin A, which 
blocks electron transport chain (ETC) inhibiting its complex 
III. On the contrary, 2,4-dinitrophenol, which uncouples (but 
does not block) ETC function from ATP generation, did not 
mimic the effects of exogenous pyruvate or antimycin A. This 
indicates that in AH130 cells glycolytic energy production is 
FiGURe 1 | Role of cellular Redox state in the control of cell cycling. 
The core of the metabolic network controlling AH130 hepatoma cell cycling is 
the cellular RedOx state expressed by the cytosolic NADP/NADPH ratio. The 
transfer of reducing equivalents (H+) from methylene-tetrahydro-folate 
(CH2-FH4) to NADP, generating methenyl-tetrahydro-folate (CH-FH4) and 
NADPH, is a limiting step of the assembly of purine ring required for the 
amplification of purine pools indispensable for the G1–S transition of mitotic 
cycle. An accumulation of cytosolic NADPH inhibits cell recruitment into S.  
A fundamental role in the regulation of NADP/NADPH ratio is played by folate 
(F), whose reduction to tetrahydro-folate (FH4) by dehydrofolate-reductase 
(DHFR) generates NADP. When DHFR activity is impaired by the addition of 
its inhibitor Methotrexate or of an excess of the reaction product (FH4), 
NADPH increases with the consequent reductive shift of NADP/NADPH ratio 
and the inhibition of purine synthesis. However, the major antagonist of this 
shift is the transfer of cytosolic reducing equivalents onto the mitochondrial 
ETC through suitable shuttles, accounting for the crucial role of ETC in purine 
synthesis. This transfer is antagonized whenever ETC, although not inhibited, 
is saturated by reducing equivalents produced by oxidizable substrates of the 
Krebs cycle, such as pyruvate.
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sufficient and that the role of ETC is related instead to the fact 
that some pyruvate cannot be converted to lactate and needs to 
be oxidized. In other words, ETC seems necessary to prevent a 
detrimental accumulation of reducing equivalents coming from 
oxidizable substrates. In turn, an excess of oxidizable substrates 
can saturate ETC. In this respect, the differentiation state of cells 
is critical. ETC saturation is easily prevented in cells endowed 
with large mitochondrial equipment (“transit” progenitor cells 
characterized by high proliferation rate), but easily produced 
in cells with few mitochondria (21). AH130 cells possess, as a 
consequence of their adaptation to low oxygen, a very scanty 
mitochondrial apparatus, easily saturable by pyruvate at concen-
trations which are instead easily catabolized by progenitor cells. 
Thus, AH130 cells represent the prototype of stem cells that 
are vulnerable to physiological metabolites totally innocuous 
to non-stem cells. In conclusion, AH130 cell recruitment into 
S can be limited in two ways: (a) hindering respiration, either 
under oxygen shortage or by impairing the electron transport 
to oxygen using ETC inhibitors (antimycin A) and (b) saturat-
ing the ETC with an excess of oxidizable substrates (pyruvate). 
The metabolic network vulnerable to pyruvate is outlined in 
Figure 1. AH130 cell recruitment into S implies, to control the 
neo-synthesis of DNA, a tight complementation of glycolysis, 
cellular RedOx state, and folate metabolism. This recruitment 
is controlled by a cytosolic NADP-dependent step of folate 
utilization in the synthesis of purine ring, a step where NADPH 
produced is re-oxidated through the transport of reducing 
equivalents (electrons) to ETC (21, 22).
CHRONiC MYeLOiD LeUKeMiA AND THe 
MeTABOLiC CONTROL OF ONCOGeNe 
ADDiCTiON
Chronic myeloid leukemia is determined by a reciprocal 
translocation between chromosomes 9 and 22, resulting in the 
formation of the chimeric BCR/Abl protein (hereafter “BCR/
Abl”) that functions as a constitutively active tyrosine kinase. 
Tyrosine kinase inhibitors (TKI), such as imatinib-mesylate (IM), 
are highly effective to suppress BCR/Abl enzymatic activity and 
to treat chronic phase CML patients. However, in a large majority 
of patients, IM does not efficiently kill leukemic stem cells (LSC), 
the crucial event to cure CML (23). It is becoming clear that 
second-/third-generation TKI remain unable to eradicate LSC. 
Therefore, strategies directed to hit TKI-resistant LSC aiming at 
targets different from BCR/Abl are intensely sought after.
Mechanisms traditionally believed to determine resistance to 
IM and TKI are (24): (a) mutations of BCR/abl gene within the 
tyrosine kinase domain (primary or secondary to treatment), 
(b) amplification of BCR/abl, (c) mutations outside BCR/abl 
determining BCR/Abl-independent survival and proliferation, 
(d) enhanced activity of drug exporters, and (e) quiescence. 
A novel mechanism of resistance to IM emerged from our 
studies in vitro. We showed indeed, using CML cell lines, that 
a very low oxygen tension (0.1% oxygen) in the incubation 
atmosphere maintains the stem cell potential while cell growth 
is inhibited and the oncogenic BCR/Abl protein is suppressed 
(25, 26). Being deprived of BCR/Abl, LSC selected in low oxygen 
are independent of BCR/Abl signaling, i.e., they lack oncogene 
addiction (27). In spite of this, LSC selected in low oxygen 
remain genetically leukemic, so that they are capable to regen-
erate a BCR/Abl-expressing/dependent progeny (25, 26). Thus, 
BCR/Abl suppression in low oxygen is not a genetically blocked 
event, but a fully reversible phenotypical adaptation. This fact 
is in keeping with the “chiaroscuro stem cell” model proposed 
to describe the relationship between the HSC and HPC pheno-
types (28). The refractoriness to TKI of LSC of CML adapted to 
low oxygen is a straightforward consequence of the transient 
and reversible suppression of their molecular target. We defined 
“environment-enforced BCR/Abl suppression” this mechanism 
of resistance to TKI. This mechanism does not require, to explain 
the onset of resistance, to postulate the occurrence of permanent 
changes in a CML subclone due to secondary mutations (29). 
Our in vitro findings are strongly supported by the observation 
that LSC do not depend on BCR/Abl kinase activity for their 
survival (30), as well as by the clinical evidences that MRD and 
the related CML relapse following successful IM treatment is 
FiGURe 2 | Cancer stem cell models, oncogene dependence, and 
metabolic profile. Correspondence to the normal stem and progenitor cell 
phenotypes of two complementary subsets of CSC identified on the basis of 
two models for their generation. Relationship of these subsets to oxygen and 
glucose supply in tissue microenvironment as well as to the activity of 
growth-promoting oncogene signaling. CSC, cancer stem cell; CPC, cancer 
progenitor cell; MRD, minimal residual disease; the width of arrows 
corresponds to the hypothesized level of activity.
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usually sustained by cells expressing wild-type BCR/Abl (31). 
On the other hand, our model well explains: (a) the discrepancy 
observed in CML patients between the expression of BCR/abl 
transcript and that of BCR/Abl protein (32) and (b) the IM 
resistance of CML progenitors shown to be BCR/abl-positive by 
FISH or PCR (33), which we believe to be in fact transcript-
positive/protein-negative cells.
The environment-enforced BCR/Abl-negative/TKI-resistant 
phenotype implies that LSC are metabolically adapted to home 
within the “hypoxic” stem cell niches of bone marrow where HSC 
physiologically reside (see Introduction). Interestingly, we found 
that LSC adaptation to low oxygen and BCR/Abl suppression are 
not necessarily linked to quiescence (unpublished data). This is 
in keeping with the findings we obtained for HSC indicating that 
low oxygen restrains and redirects their cycling to support self-
renewal (3). The capacity of cycling in low oxygen is obviously 
crucial to allow LSC self-renewal within the stem cell niche and, 
therefore, to maintain MRD. On the other hand, as cell cycling 
is necessary for the permanent incorporation of mutations in a 
cell population, this capacity appears the key factor for neoplastic 
progression during silent/subclinical phases of the disease. Thus, 
the metabolic adaptation of LSC seems to warrant all the features 
necessary to keep CML going in a therapy-resistant fashion.
A first attempt to characterize the adaptation of LSC to a low 
oxygen environment and its relationship to BCR/Abl suppres-
sion showed that this suppression occurs when, in low oxygen, 
glucose approaches exhaustion (26). Therefore, a low-oxygen/
low-glucose environment appeared as the appropriate condition 
for the maintenance of TKI-refractory CSC sustaining MRD 
(CSC/MRD). In this respect, it is worth pointing out that glucose 
exhaustion, under our standard experimental conditions, is 
reached only after 7 days of incubation in low oxygen. Thus, it is 
evident that a cell subset exists which can stand low oxygen but 
still takes advantage of glucose availability and BCR/Abl signal-
ing. It is likely that this cell subset includes CSC that dedicate 
most of their proliferative potential to oncogene-driven clonal 
expansion, although they maintain a – probably low –  level of 
self-renewal. We are convinced that this CSC subset and the 
CSC/MRD subset correspond to the two CSC models originally 
proposed as alternative: the “CSC in normal stem cell” and the 
“CSC in normal progenitor cell” (34). Our CML data strongly 
suggest considering rather these models as complementary. The 
relationships among CSC models, self-renewal/clonal expansion 
balance, MRD, role of growth-promoting oncogene signaling, 
and dependence on oxygen and/or glucose supply are summa-
rized in Figure 2.
CONCLUDiNG ReMARKS
A question arising from the information summarized above 
was whether the Yoshida’s hepatoma and the CML models 
could complement each other contributing to define a unifying 
scenario for CSC adaptation to low oxygen. We believe that one 
can answer this question affirmatively. Indeed, AH130 hepatoma 
cells exhibit a Warburg-type metabolic profile in vitro and in vivo 
until oxygen is available, adapt to oxygen shortage relying on 
glycolysis, and undergo mitotic arrest when glucose shortage 
complicates oxygen shortage. Thus, the AH130 hepatoma rep-
resents a phenotypically homogeneous CSC-like cell population, 
which is very well suitable for biochemical, molecular, as well as 
biological studies. CML cell lines, on the other side, are hetero-
geneous populations, which retain the capacity to differentiate 
under different environmental conditions, yet, including a cell 
subset with stem cell traits. However, CML, like hepatoma, cells 
exhibit the aerobic or the anaerobic glycolytic profile depending 
on oxygen availability. Moreover, depending on glucose avail-
ability or shortage, LSC of CML cells are subjected, rather than 
to growth promotion/arrest, to a switch between two different 
CSC phenotypes characterized by different metabolic profiles. 
This phenotypical difference reflects the expression or suppres-
sion of the oncogenetic protein responsible for the disease and 
underscores the partition of CSC compartment in two subsets, 
which are dynamically related to each other and reversibly 
linked to environmental conditions. These subsets drive either 
the florid state of disease (CSC) or the maintenance of disease 
during clinical remission (CSC/MRD). Interestingly, the revers-
ibility of the two CSC phenotypes emerged from studies carried 
out using stabilized CML cell lines, in particular, K562 cells. This 
strengthens considerably the issue of the genetic identity of the 
two CSC subsets. A high percentage of K562 cells expresses ETF 
and exhibits a high level of sensitivity to pyruvate addition. Thus, 
these cells appear to share with AH130 cells important aspects 
of gene expression and metabolism profiles. On the other hand, 
it is also of high interest that the most relevant results obtained 
using stabilized CML cell lines were confirmed using a number 
of different primary explants from CML patients (26, 35). These 
findings allow to export the above conclusions about the CML 
stem cell compartment to clinical settings.
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Stem cells, besides being characterized by a high glycolytic 
activity, also consume oxygen via a functional ETC (36). Referring 
to CML, the emerging question is whether, when glucose is 
exhausted, this oxidative activity can be sufficient to sustain 
energy production from other substrates (29). This scenario 
may describe appropriately the metabolic profile of CSC/MRD, 
whereas CSC and cancer progenitor cells (CPC) would follow the 
AH130-type glucose-dependent metabolic pattern. Metabolic 
differences between quiescent or slow-cycling CSC/MRD and 
rapidly proliferating CSC/CPC are emerging from recent litera-
ture (37, 38). On the other hand, it has been demonstrated that 
a dormant subset of pancreatic cancer cells capable to survive 
oncogene ablation (like CML cells subjected to environment-
enforced BCR/Abl suppression) is responsible for tumor relapse, 
has CSC features, and relies on oxidative phosphorylation for 
survival (39). CML studies led us to envision a two-tier model 
of CML stem cell niche where different LSC subsets establish a 
sort of “metabolic symbiosis” conceptually similar to that shown 
between cancer cells and stroma within solid tumors (29). 
According to this model, a drop of oxygen tension in the niche 
periphery would stimulate glycolysis therein via the activation 
of transcriptional activity mediated by hypoxia-inducible factor 
1α (HIF1α). The consequent high rate of glucose consumption 
would determine a sharp decrease of pH and increase of lactate 
concentration in the niche core. There, low pH would inhibit 
HIF1α, and available substrates, such as lactate itself, would be 
oxidized to produce energy suitable for LSC survival.
In summary, the combination of data from the hepatoma 
and CML models led us to hypothesize the following coupling 
between metabolic profiles and functional subsets of cancer cell 
populations:
 (A) Low oxygen-sensitive CPC (proliferation directed to clonal 
expansion coupled with differentiation); high-level onco-
genetic proliferative signaling (e.g., BCR/Abl expressed); 
high-level oxidative energy production; and many (and 
elongated/cristae-rich) mitochondria.
 (B) Low oxygen-resistant self-renewing CSC (proliferation cou-
pled with commitment to clonal expansion); reduced but not 
suppressed oncogenetic proliferative signaling (e.g., BCR/
Abl undergoing suppression); upregulated glycolytic energy 
production, sustained by glucose availability (maintained 
even if oxygen supply is restored  –  Warburg effect); few 
(and rounded/cristae-poor) mitochondria; and low-level 
oxidative activity directed, rather than to provide energy, to 
prevent a detrimental accumulation of reducing equivalents 
produced in high quantities by upregulated glycolysis.
 (C) Low oxygen-adapted self-renewing CSC (prolif-
eration uncoupled with commitment to clonal expansion); 
suppressed oncogenetic proliferative signaling (e.g., BCR/
Abl suppressed); downregulated glycolytic energy produc-
tion due to glucose exhaustion; few mitochondria; and low-
level oxidative activity sufficient to sustain energetically the 
slow-cycling/quiescent cell subset responsible for MRD.
On the basis of all above, the use of metabolic inhibitors to 
target CSC emerges as a therapeutic strategy well worth being 
explored if one aims at the cure of disease, i.e., at its eradication. In 
this respect, a number of attempts have been actually carried out 
using inhibitors of the best known pathways of energy metabolism, 
such as glycolysis and mitochondrial function. These inhibitors 
include the glucose analog 2-deoxyglucose, which accumulates 
in cells and inhibits hexokinase; dichloroacetate, an inhibitor 
of pyruvate dehydrogenase kinase, which forces pyruvate to 
mitochondrial metabolism; metformin, an anti-diabetic drug 
endowed with insulin-dependent and direct insulin-independent 
anticancer effects (40–43).
Perhaps even more interesting therapeutic alternatives are rep-
resented by the use of physiological substrates related to “energy” 
metabolism. We have previously shown that peculiar metabolic 
features of cell adaptation to, and survival in, low oxygen imply 
growth restriction points that can be targeted by physiological 
factors, such as pyruvate, tetrahydrofolate, and glutamine (20). 
For instance, in the presence of pyruvate (upto 20 mM), tumors 
of various histogenesis (melanoma and neuroblastoma, in addi-
tion to AH130 hepatoma and CML) undergo growth inhibition 
in  vitro, to levels apparently proportional to their degree of 
anaplasia, being this inhibition maximal (up to 90%) for AH130 
cells. Remarkably, pyruvate is innocuous, even at the highest 
doses, to normal differentiated cells. Thus, cancer growth can be 
attacked not only via the targeting of metabolic pathways in gen-
eral but also via their targeting, in particular, using physiological 
substrates. The possibility of transferring the latter strategy to 
preclinical settings is being addressed in our laboratory.
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